AmpliPhi Completes Enrollment in Drug Trial for Hospital-Acquired Pneumonia, Other Infections
AmpliPhi Biosciences has completed enrollment for a Phase 1 clinical trial to evaluate the safety of AB-SAB01, its proprietary bacteriophage cocktail against Staphylococcus aureus (S. aureus) infections. Despite strong eradication efforts, S. ... Read more